Studies of hematopoietic stem cell transplantation for ARL
Reference . | Type and comments . | No. . | Transplantation rate . | CR at report . | Median follow-up . | OS . |
|---|---|---|---|---|---|---|
| Gabarre et al40 | Ref/rel NHL, Hodgkin; PBSC collections OK | 8 | NR | 5/8 | NR | 50% at 9 mo |
| Krishnan et al41 | Relapsed NHL, CBV preparation, 20/20 harvested, 1 delayed engraftment | 20 | 100% | 17/20 | 32 mo | 85% at 32 mo |
| Re et al42 | Ref/rel NHL, BEAM preparation, 85% PBSC collection rate | 20 | 65% | 8/16 | 12 mo | 55% at 9 mo |
| Diez-Martin et al43 | Rel/ref/high risk 1st CR NHL, Hodgkin disease | 14 | 79% | 8/14 | 30 mo | 71% at 21 mo |
Reference . | Type and comments . | No. . | Transplantation rate . | CR at report . | Median follow-up . | OS . |
|---|---|---|---|---|---|---|
| Gabarre et al40 | Ref/rel NHL, Hodgkin; PBSC collections OK | 8 | NR | 5/8 | NR | 50% at 9 mo |
| Krishnan et al41 | Relapsed NHL, CBV preparation, 20/20 harvested, 1 delayed engraftment | 20 | 100% | 17/20 | 32 mo | 85% at 32 mo |
| Re et al42 | Ref/rel NHL, BEAM preparation, 85% PBSC collection rate | 20 | 65% | 8/16 | 12 mo | 55% at 9 mo |
| Diez-Martin et al43 | Rel/ref/high risk 1st CR NHL, Hodgkin disease | 14 | 79% | 8/14 | 30 mo | 71% at 21 mo |
Ref/rel indicates refractory/relapsed; CBV, cyclophosphamide, BCNU, VC-16 (etoposide); BEAM, BCNU, etoposide, ara-C, melphalan; PBSC, peripheral-blood stem cell.